Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids

Nutrition and Cancer

Volumn 62, Issue 3, 2010, Pages 284-296

  Shaikh, Irshad A A ^a   Brown, Iain ^a   Wahle, Klaus W J ^a   Heys, Steven D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARACHIDONIC ACID; CELECOXIB; CISPLATIN; CONJUGATED LINOLEIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FULVESTRANT; GAMMA LINOLENIC ACID; GENISTEIN; ICOSAPENTAENOIC ACID; IDARUBICIN; IRINOTECAN; LINOLEIC ACID; LINOLENIC ACID; LONG CHAIN FATTY ACID; MENHADEN OIL; MITOXANTRONE; NAVELBINE; OLEIC ACID; OMEGA 3 FATTY ACID; PACLITAXEL; POLYUNSATURATED FATTY ACID; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; CELL STRAIN MCF 7; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; HUMAN; LIPID PEROXIDATION; LUNG NON SMALL CELL CANCER; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; REVIEW;

ANIMALS; ANTHRACYCLINES; BREAST NEOPLASMS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; TAMOXIFEN; TAXOIDS; VINCA ALKALOIDS;

ANIMALIA;

EID: 77951111316     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903407189     Document Type: Review

References (54)

1. Doll R: The lessons of life: keynote address to the nutrition and cancer conference. Cancer Res 52, 2024s-2029s, 1992.
2. Berquin IM, Edwards IJ, and Chen YQ: Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269, 363-377, 2008.
3. Simopoulos AP: The Mediterranean diets: what is so special about the diet of Greece? The scientific evidence. J Nutr 131, 3065S-3073S, 2001.
4. Gago-Dominguez M, Yuan JM, Sun CL, Lee HP, and Yu MC: Opposing effects of dietary n-3 and n-6 fatty acids on mammary carcinogenesis: the Singapore Chinese Health Study. Br J Cancer 89, 1686-1692, 2003.
5. Cowing BE and Saker KE: Polyunsaturated fatty acids and epidermal growth factor receptor/mitogen-activated protein kinase signaling in mammary cancer. J Nutr 131, 1125-1128, 2001.
6. Terry P, Lichtenstein P, Feychting M, Ahlbom A, and Wolk A: Fatty fish consumption and risk of prostate cancer. Lancet 357, 1764-1766, 2001. (Pubitemid 32524210)
7. Biondo PD, Brindley DN, Sawyer MB, and Field CJ: The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 19, 787-796, 2008
8. Germain E, Chajes V, Cognault S, Lhuillery C, and Bougnoux P: Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75, 578-583, 1998.
9. Plumb JA, Luo W, and Kerr DJ: Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67, 728-733, 1993.
10. Shao Y, Pardini L, and Pardini RS: Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids 30, 1035-1045, 1995.
11. Menendez JA, DelMar Barbacid M, Montero S, Sevilla E, Escrich E, et al.: Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 37, 402-413, 2001.
12. Menendez JA, Lupu R, and Colomer R: Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 14, 263-270, 2005.
13. Shaikh IA, Brown I, Schofield AC, Wahle KW, and Heys SD: Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68, 1635-1646, 2008.
14. Wolff AC, Donehower RC, Carducci MK, Carducci MA, Brahmer JR, et al.: Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9, 3589-3597, 2003.
15. Kenny FS, Pinder SE, Ellis IO, Gee JM, Nicholson RI, et al.: Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 85, 643-648, 2000.
16. Calviello G, Serini S, Piccioni E, and Pessina G: Antineoplastic effects of n-3 polyunsaturated fatty acids in combinationwith drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer 61, 287-301, 2009.
17. de Gomez Dumm IN and Brenner RR: Oxidative desaturation of alphalinoleic, linoleic, and stearic acids by human liver microsomes. Lipids 10, 315-317, 1975.
18. Mackler NJ and Pienta KJ: Drug insight: Use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2, 92-100, 112, 2005.
19. Szulawska A and Czyz M: Molecular mechanisms of anthracyclines action. Postepy Hig Med Dosw [serial online] 60, 78-100, 2006. Available at: http://www.phmd.pl/pub/phmd/vol 60/8745.pdf. Accessed January 1, 2009.
20. Mano M:Vinorelbine in the management of breast cancer: newperspectives, revived role in the era of targeted therapy. Cancer Treat Rev 32, 106-118, 2006.
21. Leveque D and Jehl F: Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 31, 184-197, 1996.
22. GradisharWJ: Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7, 1041-1053, 2006.
23. Menendez JA, Ropero S, Lupu R, and Colomer R: Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep 11, 1241-1252, 2004.
24. Wang Z, Butt K, Wang L, and Liu H: The effect of seal oil on paclitaxel induced cytotoxicity and apoptosis in breast carcinoma MCF-7 and MDAMB- 231 cell lines. Nutr Cancer 58, 230-238, 2007.
25. Wahle KWJ, Heys SD, and Rotondo D: Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res 43, 553-587, 2004.
26. Fite A, Goua M, Wahle KJ, Schofield A, Hutcheon A, et al.: Potentiation of the anti-tumour effect of docetaxel by conjugated linoleic acids (CLAs) in breast cancer cells in vitro. Prostaglandins Leukot Essent Fatty Acids 77, 87-96, 2007.
27. Maheo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, et al.: Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39, 742-751, 2005.
28. Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J, et al.: Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44, 1483-1491, 2008.
29. Davies CL, Loizidou M, CooperAJ, and Taylor I: Effect of gamma-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. Eur J Cancer 35, 1534-1540, 1999.
30. Vibet S, Maheo K, Gore J, Dubois P, Bougnoux P, et al.: Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos 35, 822-828, 2007.
31. Menendez JA, Ropero S, del Barbacid MM, Montero S, Solanas M, et al.: Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treat 72, 203-219, 2002.
32. DeGraffenried LA, FriedrichsWE, Fulcher L, FernandesG, Silva JM, et al.: Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 14, 1051-1056, 2003.
33. Horia E andWatkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 28, 809-815, 2007.
34. Menendez JA, Colomer R, and Lupu R: Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. Int J Cancer 109, 949-954, 2004.
35. Nakagawa H, Yamamoto D, Kiyozuka Y, Tsuta K, Uemura Y, et al.: Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J Cancer Res Clin Oncol 126, 448-454, 2000.
36. Chen J, Power KA, Mann J, Cheng A, and Thompson LU: Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood) 232, 1071-1080, 2007.
37. Menendez JA, Vellon L, Colomer R, and Lupu R: Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol 16, 359-371, 2005.
38. Flowers M and Thompson PA: t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2. PLoS One 4, e5342, 2009.
39. Narayanan NK, Narayanan BA, and Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol 26, 785-792, 2005.
40. Narayanan NK, Narayanan BA, Bosland M, Condon MS, and Nargi D: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer 119, 1586-1598, 2006.
41. Hardman WE, Avula CP, Fernandes G, and Cameron IL: Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7, 2041-2049, 2001.
42. Hardman WE, Moyer MP, and Cameron IL: Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 81, 440-448, 1999.
43. Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, et al.: The role of dietary supplements during cancer therapy. J Nutr 133, 3794S-3799S, 2003.
44. Colas S, Germain E, Arab K, Maheo K, Goupille C, et al. Alpha-tocopherol suppresses mammary tumor sensitivity to anthracyclines in fish oil-fed rats. Nutr Cancer 51, 178-183, 2005.
45. Shao Y, Pardini L, and Pardini RS: Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr Cancer 28, 63-73, 1997.
46. Connolly JM, Coleman M, and Rose DP: Effects of dietary fatty acids on DU145 human prostate cancer cell growth in athymic nude mice. Nutr Cancer 29, 114-119, 1997.
47. Colas S, Maheo K, Denis F, Goupille C, Hoinard C, et al.: Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin Cancer Res 12, 5879-5886, 2006.
48. Harries M, O'Donnell A, Scurr M, Reade S, Cole C, et al.: Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br J Cancer 91, 1651-1655, 2004.
49. Guminski AD, Harnett PR, and deFazio A: Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line-a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48, 229-234, 2001.
50. Bougnoux P, Hajjaji N, Baucher MA, Jourdan M, Goupille C, et al.: Docosahexaenoic acid (DHA) intake during first-line chemotherapy improves survival in metastatic breast cancer. AACR Meeting Abstracts 2006:1237-a; 2006. Available at http://aacrmeetingabstracts. org/cgi/content/abstract/2006/1/1237- a. Accessed January 8, 2009.
51. Kenny FS, Gee JM, Nicholson RI, Ellis IO, Morris TM, et al.: Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. Int J Cancer 92, 342-347, 2001.
52. Simopoulos AP: The traditional diet of Greece and cancer. Eur J Cancer Prev 13, 219-230, 2004.
53. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, et al.: Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7, 3229-3238, 2001.
54. Siddiqui RA, Zerouga M, Wu M, Castillo A, Harvey K, et al.: Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res 7, R645-R654, 2005.